Pfizer Valuation

Is PFED undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PFED when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PFED (€25.01) is trading below our estimate of fair value (€74.71)

Significantly Below Fair Value: PFED is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for PFED?

Key metric: As PFED is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PFED. This is calculated by dividing PFED's market cap by their current earnings.
What is PFED's PE Ratio?
PE Ratio35x
EarningsUS$4.27b
Market CapUS$149.38b

Price to Earnings Ratio vs Peers

How does PFED's PE Ratio compare to its peers?

The above table shows the PE ratio for PFED vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22x
AZN AstraZeneca
30.8x18.2%UK£159.0b
GSK GSK
21.5x23.2%UK£53.9b
HIK Hikma Pharmaceuticals
19.1x12.2%UK£4.3b
NOVN Novartis
16.5x7.0%CHF 173.4b
PFED Pfizer
35x14.8%€149.4b

Price-To-Earnings vs Peers: PFED is expensive based on its Price-To-Earnings Ratio (35x) compared to the peer average (22x).


Price to Earnings Ratio vs Industry

How does PFED's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
No. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: PFED is expensive based on its Price-To-Earnings Ratio (35x) compared to the European Pharmaceuticals industry average (19.3x).


Price to Earnings Ratio vs Fair Ratio

What is PFED's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PFED PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PFED's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PFED forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€25.01
€30.74
+23.0%
14.5%€43.42€24.12n/a23
Dec ’25€24.44
€30.86
+26.3%
13.8%€42.53€23.63n/a23
Nov ’25€26.13
€30.72
+17.6%
13.1%€41.37€24.82n/a23
Oct ’25€26.01
€30.06
+15.6%
13.4%€40.30€24.18n/a22
Sep ’25€25.96
€30.17
+16.2%
13.0%€40.85€24.51n/a22
Aug ’25€28.72
€30.36
+5.7%
13.8%€41.56€24.93n/a22
Jul ’25€26.02
€29.42
+13.1%
15.1%€41.48€24.89n/a22
Jun ’25€26.05
€29.42
+12.9%
15.1%€41.48€24.89n/a22
May ’25€24.10
€29.47
+22.3%
15.4%€41.94€24.23n/a22
Apr ’25€25.80
€30.26
+17.3%
18.6%€46.27€24.06n/a22
Mar ’25€24.85
€30.27
+21.8%
18.4%€46.26€24.06n/a23
Feb ’25€25.15
€30.36
+20.7%
19.3%€46.00€23.92n/a22
Jan ’25€25.85
€29.76
+15.1%
19.9%€45.03€20.71n/a22
Dec ’24€27.90
€37.16
+33.2%
23.1%€68.96€29.42€24.4422
Nov ’24€29.05
€38.72
+33.3%
22.4%€70.97€30.28€26.1322
Oct ’24€30.80
€41.57
+35.0%
21.3%€70.19€29.95€26.0122
Sep ’24€33.00
€40.96
+24.1%
21.0%€69.40€29.61€25.9623
Aug ’24€32.65
€41.60
+27.4%
19.9%€68.29€31.87€28.7223
Jul ’24n/a
€42.61
0%
19.2%€69.01€32.20€26.0222
Jun ’24n/a
€43.38
0%
18.8%€69.71€32.53€26.0522
May ’24n/a
€44.75
0%
16.1%€68.37€36.46€24.1022
Apr ’24n/a
€46.88
0%
16.0%€69.63€37.14€25.8022
Mar ’24n/a
€48.05
0%
15.3%€70.19€37.43€24.8521
Feb ’24n/a
€46.96
0%
15.1%€68.27€36.41€25.1521
Jan ’24n/a
€51.00
0%
12.3%€70.20€41.18€25.8521
Dec ’23n/a
€51.88
0%
12.6%€72.35€42.45€27.9021

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 00:14
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/29
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pfizer Inc. is covered by 55 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Alistair CampbellBerenberg